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Abstract
Glioblastomas are malignant brain tumors that are
rarely curable, even with aggressive therapy (surgery,
chemotherapy, and radiation). Glioblastomas fre-
quently display loss of PTEN and/or epidermal growth
factor receptor activation, both of which activate the
PI3Kpathway. Thispathwaycan increasevascular endo-
thelial growth factor (VEGF) and hypoxia-inducible
factor (HIF)-1A expression. We examined the effects of
two human immunodeficiency virus protease inhibi-
tors, nelfinavir and amprenavir, which inhibit Akt sig-
naling, on VEGF and HIF-1A expression and on
angiogenesis. Nelfinavir decreased VEGF mRNA ex-
pression and VEGF secretion under normoxia. Down-
regulation of P-Akt decreased VEGF secretion in a
manner similar to that of nelfinavir, but the combination
of the two had no greater effect, consistent with the
idea that nelfinavir decreases VEGF through the PI3K/
Akt pathway. Nelfinavir also decreased the hypoxic
induction of VEGF and the hypoxic induction of HIF-
1A, which regulates VEGF promoter. The effect of
nelfinavir on HIF-1A was most likely mediated by de-
creased protein translation. Nelfinavir’s effect on VEGF
expression had the functional consequence of decreas-
ing angiogenesis in in vivoMatrigel plug assays. Similar
effects onVEGFandHIF-1A expressionwere seenwith a
different protease inhibitor, amprenavir. Our results
support further research into these protease inhibitors
for use in future clinical trials for patients with glio-
blastoma multiformes.
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Introduction
Glioblastoma multiforme (GBM), the most common brain
tumor in adults, remains a difficult therapeutic challenge.
GBMs are infiltrative high-grade gliomas that are associated
with dismal survival in spite of aggressive therapy, including
surgery, radiotherapy, and temozolomide [1]. For this rea-
son, novel strategies, including antiangiogenic therapies,
are being employed in the treatment of these tumors [2,3].
These strategies are motivated by the fact that glio-
blastomas often express very high levels of vascular endo-
thelial growth factor (VEGF), a key mediator of blood vessel
growth [4,5]. In other solid malignancies, the anti-VEGF mono-
clonal antibody bevacizumab has been shown to prolong sur-
vival when used in combination with chemotherapy [6].
A key stimulus for increased VEGF expression in glio-
blastomas is hypoxia, which is prevalent in these tumors [7,8]
and leads to stabilization and increased expression of the a
subunit of the transcription factor hypoxia-inducible factor
(HIF)-1 [9]. HIF-1a heterodimerizes with HIF-1b, whose level
does not vary with oxygen concentration, to transactivate an
array of genes, many of which are involved in angiogenesis,
glucose transport and metabolism, and tumor invasion and
metastasis [8,9]. In a number of tumor xenograft models,
decreased HIF-1a expression is associated with slower growth
[10–12]. Knockout of HIF-1a has been reported to decrease
in vitro growth even under normoxic conditions [13]. In some
solid tumors, there is a correlation between high levels of HIF-
1a and worse clinical outcome [14–16]. There is increasing
expression of HIF-1a with increasing glioma grade, which also
correlates with worsening prognosis [17]. For these reasons,
many feel that both HIF-1a and VEGF are excellent targets for
cancer therapy [2,8,9].
The PI3K pathway is commonly activated in glioblastomas,
often by PTEN mutation but also possibly by epidermal growth
factor receptor overexpression or activation by mutations
[18,19]. Studies from our laboratory [20,21] and others [22,23]
have confirmed a link between PI3K/Akt pathway activation and
increased VEGF and HIF-1a expression. Recently, it has been
shown that protease inhibitors, such as nelfinavir, currently
used to treat human immunodeficiency virus (HIV) patients
can radiosensitize tumor cells, possibly through inhibition of
PI3K/Akt signaling [24]. Therefore, wewere interested in testing
whether these compounds could inhibit VEGF and HIF-1a
expression in glioblastomas. We performed studies to examine
the effects of two of these HIV protease inhibitors, nelfinavir
and amprenavir, on VEGF and HIF-1a expression in vitro and
on angiogenesis in vivo.
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Materials and Methods
Tissue Culture and Reagents
U87MG was obtained from the American Type Culture
Collection (Rockville, MD). U251MG was obtained from the
Brain Tumor Research Center Tissue Bank at the University
of California San Francisco (San Francisco, CA). Both cell
lines were cultured in Dulbecco’s modified Eagle’s medium
(4500 mg/l glucose; Invitrogen, Carlsbad, CA) containing
10% fetal bovine serum (Atlanta Biologicals, Lawrenceville,
GA) and grown in an incubator containing 5% carbon dioxide
and 21% oxygen. U87/PTEN doxycycline– inducible cells
were a gift from M. Georgescu (M. D. Anderson Cancer
Center, Houston, TX) [25]. These cells were cultured in
the same medium used for U87MG cells, but with G418
(400 mg/ml) and blasticidin (2 mg/ml) added.
Hypoxic conditions were established as described pre-
viously [26,27]. Cells were plated onto 60-mm Permanox
dishes (Munc, Rochester, NY) that were permeable to oxy-
gen andwere allowed to attach overnight. Immediately before
the induction of hypoxia, the medium was replaced with 2 ml
of fresh HEPES-buffered medium. Each dish was sealed in
an aluminum chamber, and pO2 was decreased to the
desired level by using a series of precision evacuations
followed by replacement with nitrogen (gas exchange). After
warming, the chambers were shaken continuously at 37jC
to ensure that pO2 in the culture medium was in equilibrium
with pO2 in the gas phase.
Northern Blot Analysis
Northern blot analysis was performed as described pre-
viously [21].
Protein Extraction and Western Blot Analysis
For details regarding protein isolation, gel electrophoresis,
and Western blot analysis, see Pore et al. [28]. The following
antibodies were used: monoclonal anti–phospho-Akt anti-
body that recognizes P-S473 (NewEngland Biolabs, Ipswich,
MA), anti-Akt antibody (New England Biolabs), anti–HIF-1a
antibody (clone H1a67; Novus Biologicals, Littleton, CO) at
1:1000 dilution, and anti–b-actin antibody (Sigma-Aldrich,
St. Louis, MO) at 1:1000 dilution. The secondary antibody
used for these blots was a goat anti-mouse antibody (BioRad,
Hercules, CA). Antibody binding was detected by chemi-
luminescence using an ECL kit (Amersham Pharmacia,
Piscataway, NJ).
VEGF Enzyme-Linked Immunosorbent Assay (ELISA)
An aliquot of conditioned medium was removed for stor-
age at 80jC. VEGF protein concentration in the medium
was determined by ELISA using a commercial kit (R&D
Systems, Minneapolis, MN).
In Vivo Study of Angiogenesis Using Matrigel Plug Assay
Pathogen-free female Ncr-nu/numice were obtained from
Taconic Industries (Germantown, NY) and housed in animal
facilities of the University Laboratory Animal Resources and
the Institute for Human Gene Therapy of the University of
Pennsylvania (Philadelphia, PA). All experiments were car-
ried out in accordance with the guidelines of the University
Institutional Animal Care and Use Committee. Angiogenesis
was measured in growth factor–free Matrigel (Collaborative
Biomedical Products, Inc., Bedford, MD). Matrigel plugs
(500 ml) containing 2 106 cells of each cell line were injected
subcutaneously into the right and left sides of 4- to 8-week-
old female BALB/c nude mice at sites lateral to the ab-
dominal midline. As negative control, Matrigel with 100 ml of
phosphate-buffered saline (PBS) was injected in a similar
manner. All measurements were made in triplicate. Animals
were sacrificed 5 days after Matrigel injection. Matrigel
plugs were recovered and photographed immediately. Plugs
were then dispersed in PBS and incubated overnight at
4jC. Using Drabkin’s solution (Sigma-Aldrich), hemoglobin
levels were determined according to the manufacturer’s in-
structions. Hemoglobin level was calculated from a standard
hemoglobin curve.
Statistical Analysis
Two-sided Student’s t test was employed to compare the
means between two groups (i.e., hemoglobin levels in Matri-
gel plugs between control and nelfinavir-treated mice).
Results
Nelfinavir Downregulates VEGF and HIF-1 Expression
through Inactivation of PI3K/Akt Pathways
U87MG cells activate the PI3K/Akt pathway through loss
of PTEN [29]. Nelfinavir inhibited Akt phosphorylation at
serine 473 in human glioblastoma U87MG cells (Figure 1A).
Phospho-Akt levels had decreased by 24 hours and had al-
most completely disappeared by 72 hours, whereas total Akt
and b-actin levels were unchanged. Because the PI3K path-
way regulates VEGF expression, we investigated the effect
of nelfinavir on this. We found that nelfinavir dramatically
decreases VEGF mRNA expression (Figure 1B). In addition
to the effects of nelfinavir on VEGF expression under nor-
moxia, the drug also blunted the induction of HIF-1a in re-
sponse to hypoxia (Figure 1C). Likewise, nelfinavir also
decreased VEGF secretion under normoxic and under hyp-
oxic conditions, as determined by ELISA (Figure 1D).
Nelfinavir Decreases Angiogenesis In Vivo
To determine whether nelfinavir-induced decrease in
VEGF secretion in vitro had a functional consequence, we
performed in vivoMatrigel assays. U87MG cells were placed
into Matrigel plugs, which were implanted subcutaneously
into nude mice. Five days later, the plugs were excised and
evaluated for hemoglobin content. Nelfinavir decreased
angiogenesis by visual inspection and hemoglobin measure-
ment (Figure 2, A and B).
Nelfinavir Downregulates HIF-1a through Inhibition
of Protein Synthesis
We wished to determine the mechanism by which nelfi-
navir decreased HIF-1a protein levels. HIF-1a undergoes
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rapid degradation by the proteasome under normoxic con-
ditions [30,31]. Treatment of cells with the proteasomal
inhibitor MG132 led to accumulation of HIF-1a under nor-
moxia, as expected. However, pretreatment with nelfinavir
prevented HIF-1a accumulation in the presence of MG132
(Figure 3A, cf. lanes 3 and 7 or lanes 4 and 8), suggesting
that nelfinavir interfered with HIF-1a synthesis rather than
with degradation. However, nelfinavir did not alter the level
of HIF-1a mRNA (data not shown), thus indicating that it
acted at the translational or the posttranslational level.
Similar results were obtained by downregulating P-Akt ex-
pression in U87MG cells. To do this, we used a derivative cell
line engineered such that addition of doxycycline induces
wild-type PTEN [25]. We confirmed that P-Akt was down-
regulated in response to doxycycline (Figure 3B). Figure 3B
shows that, when P-Akt was downregulated, the accumula-
tion of HIF-1a in the presence of MG132 was impaired
(compare lanes 3 and 7 or lanes 4 and 8). These results
suggest that inactivation of the PI3K/Akt pathway by PTEN
decreases HIF-1a protein synthesis in the same way that
nelfinavir does and is consistent with the idea that inhibi-
tion of HIF-1a expression by nelfinavir occurs through the
PI3K pathway.
To examine whether nelfinavir’s ability to downregulate
P-Akt and VEGF expression lie in a common pathway, we
performed an epistasis-type analysis. Decreasing P-Akt
levels in U87/PTEN cells by adding doxycycline decreased
VEGF secretion to a similar extent as did the addition of
nelfinavir; however, the combination of the two did not have
an additive effect (Figure 3C). This suggests that nelfinavir
decreases VEGF secretion through the Akt pathway.
Protease Inhibitor Amprenavir Inhibits VEGF and HIF-1
Expression in Glioblastoma Cells But Not in Normal
Human Astrocytes
We tested another HIV protease inhibitor, amprenavir,
which has been reported to inhibit Akt phosphorylation
[24]. We confirmed that this drug inhibited the phosphory-
lation of Akt at serine 473 in U87MG cells (Figure 4A).
Phospho-Akt levels had substantially decreased by 72 hours,
whereas total Akt and b-actin levels were unchanged. Ampre-
navir, similar to nelfinavir, also decreased VEGF mRNA
(Figure 4B) and protein expression (data not shown). Ampre-
navir also decreased the induction of HIF-1a in response to
hypoxia (Figure 4C).
To generalize our findings, we used U251MG, another
GBM cell line with increased P-Akt levels secondary to PTEN
mutation [29]. In this cell line, both amprenavir and nelfinavir
decreased VEGF secretion. In contrast, in immortalized
human astrocytes (NHA) [32], which have wild-type PTEN
and express very little VEGF, neither nelfinavir nor amprena-
vir, had any effect on VEGF expression.
Figure 1. Nelfinavir decreases VEGF expression. (A) U87MG cells were treated with nelfinavir (NFV) (15 M) for various lengths of time, as indicated. Then cells
were harvested, and Western blot analysis was performed. The membrane was probed for phospho-Akt (S473), then subsequently reprobed for total Akt and
-actin (loading control). (B) U87MG cells were treated with nelfinavir for 24 hours (NFV); thereafter, cells were harvested for RNA, and Northern blot analysis was
performed for VEGF and 18S (loading control). (C) U87MG cells were treated with nelfinavir (15 M) for 24 hours, then cells were exposed to hypoxia (0.2%
oxygen). Three hours later, cells were harvested for protein, and Western blot analysis was performed with HIF-1a antibody. Subsequently, membranes were
reprobed for -actin (loading control). (D) Cell culture medium was sampled 30 hours after nelfinavir treatment and/or hypoxia (0.2% O2). VEGF protein levels were
determined by ELISA and normalized to the number of cells in each dish.
HIV Protease Inhibitor Decreases VEGF and HIF-1A Pore et al. 891
Neoplasia . Vol. 8, No. 11, 2006
Discussion
U87MG is a commonly used glioblastoma cell line that has
been well-characterized. It displays loss of PTEN, leading to
activation of the PI3K/Akt pathway. In vitro studies show
these cells to have a high basal level of motility [33]. They
also show a high degree of invasion through normal brain
tissues [34]. Furthermore, U87MG cells show high resistance
to radiation [35]. Hence, U87MG cells recapitulate many of
the features of glioblastomas that make them hard to cure.
Figure 3. Nelfinavir decreases HIF-1a expression through alteration of
protein translation.(A) U87MG cells were treated with 15 M nelfinavir for
24 hours, then cells were exposed to the proteasome inhibitor MG132
(10 M) for various durations of time, as indicated. (B) U87/PTEN– inducible
cells were treated with doxycycline (2 g/ml) for 16 hours, then cells were
exposed to the proteasome inhibitor MG132 (10 M) for various time periods,
as indicated. For both (A) and (B), cells were harvested for protein, and
Western blot analysis was performed for HIF-1a, P-Akt, and -actin. (C)
U87MG/PTEN cells were treated with doxycycline (DOX) for 16 hours, then
cells were further treated for an additional 24 hours with nelfinavir (NFV) or
control carrier (ethanol). Then the culture medium was sampled to determine
VEGF protein levels by ELISA and was normalized to the number of cells in
each dish. *The comparison of ELISA values between these two groups
(control and doxycycline-treated U87/PTEN cells) was statistically significant
at P < .01 (two-sided Student’s t test). Comparisons between control and
nelfinavir-treated or nelfinavir + doxycycline– treated cells were also statisti-
cally significant (P < .01).
Figure 2. Nelfinavir inhibits in vivo angiogenesis. (A) Matrigel mixture
containing U87MG cells was injected subcutaneously into nude mice at sites
lateral to the abdominal midline. Four mice were given feeds containing
nelfinavir (40 mg/kg per day), and another three mice were given feeds
without nelfinavir. As negative control, Matrigel containing 100 l of PBS was
injected into two mice. Five days later, the animals were sacrificed, Matrigel
plugs were recovered and photographed immediately. Each discrete mass
represents a plug removed from a different animal. (B) The relative level of
hemoglobin present in each plug was determined using a commercially
available kit. The hemoglobin level normalized to the weight of each Matrigel
plug is plotted on the y-axis. *The comparison of mean hemoglobin values
between these two groups (control and nelfinavir-treated mice injected with
Matrigel plugs containing U87MG cells) was statistically significant at P < .01
(two-sided Student’s t test).
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New therapies are desperately needed to treat these tumors.
We show in this paper that the HIV protease inhibitors
nelfinavir and amprenavir can downregulate both VEGF
and HIF-1a and can decrease angiogenesis in U87MG cells.
We believe that the mechanism by which HIV protease
inhibitors downregulate VEGF and HIF-1a involves inhibition
of the PI3K pathway. This pathway has been shown to reg-
ulate HIF-1a [20,22,23]. The downregulation of VEGF by
these protease inhibitors is likely multifactorial as VEGF
can be regulated by the PI3K pathway through both HIF-
1adependent and HIF-1a– independent mechanisms
[21,28].Wehave some evidence that these drugs act through
the PI3K pathway to decrease VEGF and HIF-1a expression,
although this may not be the complete story. If this is an
important mechanism, this may give these drugs some
specificity in targeting tumor cells. GBMs often display acti-
vation of the PI3K/Akt pathway [18,19]. This pathway should
not be active in most normal tissues; therefore, in theory, its
inhibition should increase the therapeutic ratio by enhancing
tumor cell killingwhile sparing normal tissues. Consistent with
this, we did not find these drugs to lead to any decrease in
VEGF expression in immortalized human astrocytes (NHA).
In contrast, in U87MG and U251MG cells, both of which
display activation of the PI3K/Akt pathway secondary to
PTEN mutation, nelfinavir decreased VEGF secretion.
These findings may have important clinical implications.
There is currently great interest in identifying VEGF and
HIF-1a inhibitors for use as antitumor agents. The protease
inhibitors nelfinavir and amprenavir inhibit both of these
targets. Although some studies suggest that inhibition of
either of these targets by themselves may be sufficient to
inhibit tumor growth, it is very possible that this inhibition
must be combined with other modalities to be of clinical
benefit. In one study, reduction of VEGF secretion in U87
cells using siRNA was not able to reduce tumor growth; how-
ever, when coupled to the antiangiogenic effect of IL-4, tumor
growth was totally abolished [36]. Clinical studies that
yielded positive results using the anti-VEGF monoclonal
antibody bevacizumab have used it in conjunction with con-
ventional chemotherapy [37]. For example, in a phase III
randomized trial for metastatic colon cancer, patients who
received standard chemotherapy and bevacizumab had im-
proved survival compared to those who received chemo-
therapy and placebo [6].
In particular, the combination of anti-VEGF therapy and
radiation is attractive [38,39]. One group reported that secre-
tion of VEGF is increased by irradiation of GBM lines, which
led them to speculate that this might be associated with
radioresistance that could be countered using an anti-VEGF
agent [40]. Several reports in the literature suggest that
decreasing VEGF expression following radiation can aug-
ment the response of tumors to radiation in vivo [41–43].
Inhibition of HIF-1a decreases VEGF but also has the added
benefit of decreasing the expression of other genes that
Figure 4. Amprenavir inhibits the expression of HIF-1a and VEGF. (A) U87MG cells were treated with 15 M amprenavir (AMP) for various lengths of time, as
indicated. Then cells were harvested, and Western blot analysis was performed. The membrane was probed for P-Akt (S473) and total Akt, and then was reprobed
for -actin (loading control). (B) U87MG cells were treated with amprenavir for 24 hours; thereafter, cells were harvested for RNA, and Northern blot analysis was
performed for VEGF and 18S (loading control). (C) U87MG cells were treated with amprenavir (15 M) for 24 hours, then cells were exposed to hypoxia (0.2%
oxygen). Three hours later, cells were harvested, and Western blot analysis was performed for HIF-1a. Membranes were then reprobed for -actin (loading
control). (D and E) U251MG or NHA cells were treated with nelfinavir (NFV) or amprenavir. Thirty hours later, the cell culture medium was collected, and VEGF
protein levels were determined by ELISA and normalized to the number of cells in each dish. *The comparison of ELISA values between these two groups (control
and amprenavir-treated U251MG cells) was statistically significant at P < .01 (two-sided Student’s t test). The comparison between control and NFV-treated
U251MG cells was also statistically significant (P < .01).
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might promote survival, such as those affecting glucose
metabolism. A number of putative HIF-1a inhibitors have
been identified, and many of them are currently being tested
in clinical trials [44]. mTOR inhibitors such as CCI-779 have
been shown to inhibit HIF-1a activity [45] and have shown
efficacy in phase II clinical trials, especially in renal cell carci-
noma. However, as in the case of VEGF inhibitors, HIF-1a
inhibitors may prove even more useful when used in combi-
nation with conventional therapies. In support of this idea, a
recent report suggests that HIF-1 blockade can promote
tumor radiosensitization [46]. Previous results from our group
indicate that protease inhibitors can radiosensitize cells both
in vitro and in vivo [24]. The results in the current report
suggest a potential mechanism by which these agents may
radiosensitize tumors in vivo—by inhibition of HIF-1a/VEGF.
One advantage to these drugs is that they have been in
clinical use in HIV patients for over a decade, with relatively
little toxicity [47]. Hence, they could be used in future clinical
trials in patients with glioblastomas.
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